Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma

Inhaled therapy is often considered the cornerstone of asthma management and international guidelines recommend combination therapy of inhaled corticosteroids (ICS) and long-acting-beta2-agonists (LABA) in a large proportion of asthmatic patients. The effectiveness of ICS/LABA is dependent on the co...

Full description

Saved in:
Bibliographic Details
Published inExpert review of respiratory medicine Vol. 10; no. 5; p. 481
Main Authors Crisafulli, Ernesto, Zanini, Andrea, Pisi, Giovanna, Pignatti, Patrizia, Poli, Gianluigi, Scuri, Mario, Chetta, Alfredo
Format Journal Article
LanguageEnglish
Published England 03.05.2016
Subjects
Administration, Inhalation
Anti-Asthmatic Agents - administration & dosage
Anti-Asthmatic Agents - therapeutic use
Asthma - drug therapy
Beclomethasone - administration & dosage
Beclomethasone - therapeutic use
Drug Combinations
Dry Powder Inhalers
Formoterol Fumarate - administration & dosage
Formoterol Fumarate - therapeutic use
Humans
Metered Dose Inhalers
Treatment Outcome
fixed combination
beclometasone dipropionate/formoterol fumarate
extrafine
inflammation
pMDI
small airways
DPI
Asthma
Online AccessGet more information

Cover

More Information
Summary:Inhaled therapy is often considered the cornerstone of asthma management and international guidelines recommend combination therapy of inhaled corticosteroids (ICS) and long-acting-beta2-agonists (LABA) in a large proportion of asthmatic patients. The effectiveness of ICS/LABA is dependent on the correct choice of device and proper inhalation technique, this influences drug delivery and distribution along the bronchial tree, including the most peripheral airways. The fixed combination of beclometasone dipropionate/formoterol fumarate (BDP/FF) is the only extrafine formulation available in pressurized metered dose inhaler (pMDI) and in dry powder inhaler (DPI). Here, we focus on the recent significant advances regarding BDP/FF fixed combination for the treatment of asthma.
ISSN:1747-6356
DOI:10.1586/17476348.2016.1161508